Clinical Trial Update: Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating rituximab, lenalidomide, acalabrutinib, and tafasitamab (alone and with chemotherapy) for newly diagnosed non-germinal center …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Diffuse Large B-Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING